Drugs / Hecolin®
Hecolin®
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05808166 | May 2024 → Nov 2025 overdue | hepatitis E virus infection | International Vaccine Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06306196 | Apr 2024 → Jan 2026 overdue | hepatitis E virus infection | International Vaccine Institute | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05415345 | Oct 2021 → Nov 2022 | hepatitis E virus infection, human papilloma virus infection | Xiamen Innovax Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT03365921 | Oct 2018 → Jun 2019 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02759991 Comparator | Oct 2017 → Sep 2019 | hepatitis E virus infection | Norwegian Institute of Public Health | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Xiamen Innovax Biotech Co., Ltd | Results HPV疫苗与戊型肝炎疫苗联合接种研究结果发表于国际期刊 innovax.cn ↗
研究结果显示，完成全程接种后，联合接种组与单独接种组均实现100%血清阳转。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Xiamen Innovax Biotech Co., Ltd | HPV疫苗与戊型肝炎疫苗联合接种研究结果发表于国际期刊 innovax.cn ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hecolin | “An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency” NCT03365921 ↗ |
| Known as | HEV239 | “Our aim was to assess efficacy and safety of a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China) in a randomised, double-blind,...” PMID 20728932 ↗ Aug 20101“HEV239 (Hecolin®), a recombinant vaccine containing the immunodominant protruding (E2) domain of the HEV capsid protein” PMID 40733519 ↗ Jun 2025 |
| Known as | p239 | “This is consistent with the fact that p239 was demonstrated to be an effective prophylactic vaccine (recently licensed as Hecolin(®) in China) against HEV-induced hepatitis in...” PMID 24662711 ↗ Mar 2014 |
| Known as | Recombinant Hepatitis E Vaccine (Escherichia Coli) | “An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency” NCT03365921 ↗ |
| Modality | Vaccine | “HEV239 (Hecolin®), a recombinant vaccine” PMID 40733519 ↗ Jun 2025 |
| Route | Intramuscular | “Eligible non-pregnant women (aged 16-39 years) were vaccinated intramuscularly on day 0, at 1 month, and at 6 months” PMID 39030060 ↗ Aug 2024 |